Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

PURPOSE: Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. PATIENT...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Piekarz, Richard L., Frye, Robin, Turner, Maria, Wright, John J., Allen, Steven L., Kirschbaum, Mark H., Zain, Jasmine, Prince, H. Miles, Leonard, John P., Geskin, Larisa J., Reeder, Craig, Joske, David, Figg, William D., Gardner, Erin R., Steinberg, Seth M., Jaffe, Elaine S., Stetler-Stevenson, Maryalice, Lade, Stephen, Fojo, A. Tito, Bates, Susan E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2009
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2773225/
https://ncbi.nlm.nih.gov/pubmed/19826128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6150
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky